Related Experiment Video
Updated: Jul 16, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Medical management of atrial fibrillation: future directions
1Department of Internal Medicine (Cardiology Division), University of Washington School of Medicine, Seattle, Washington 98195-6422, USA. rpage@u.washington.edu
Insights
New anti-arrhythmic drugs aim for greater efficacy and safety in treating atrial fibrillation. Research focuses on atrial-selective agents to minimize cardiac and non-cardiac toxicities, offering improved patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Electrophysiology
Background:
- Atrial fibrillation is the most prevalent arrhythmia requiring treatment.
- Current anti-arrhythmic drugs possess limited efficacy and significant toxicity.
- Cardiac toxicity includes QT prolongation and torsades de pointes; amiodarone has non-cardiac toxicities.
Purpose of the Study:
- To review current limitations of anti-arrhythmic drug therapy for atrial fibrillation.
- To explore novel therapeutic strategies targeting ion channels for improved atrial fibrillation treatment.
- To highlight the development of atrial-selective anti-arrhythmic agents.
Main Methods:
- Review of existing anti-arrhythmic drugs and their toxicities.
- Investigation of investigational agents targeting multiple ion channels or amiodarone analogs.
- Focus on drugs affecting novel ion channel targets, specifically I(TO) and I(Kur) currents.
Main Results:
- Investigational agents show promise by targeting multiple ion channels or acting as amiodarone analogs.
- Drugs inhibiting atrial-specific currents (I(TO), I(Kur)) demonstrate potential for atrial anti-arrhythmic effects without ventricular pro-arrhythmia.
- Future drugs may target remodeled atria, offering selectivity for atrial fibrillation patients.
Conclusions:
- Developing new anti-arrhythmic drugs with enhanced efficacy and safety is crucial.
- Atrial-selective agents offer a promising therapeutic avenue by minimizing pro-arrhythmic and non-cardiac toxicities.
- Targeting specific ion channels and remodeled atrial tissue may lead to safer and more effective atrial fibrillation treatments.
Abstract:
Atrial fibrillation is the most common arrhythmia that requires treatment, and although ablation is appropriate in many cases, anti-arrhythmic drug therapy remains the first and most appropriate therapy in most patients. Currently available antiarrhythmic drugs are limited by modest efficacy and significant toxicity. Cardiac toxicity relates to effects on the ventricle, especially in prolonging the QT interval and causing torsades de pointes. Amiodarone, an agent with multiple antiarrhythmic effects, is unique in its relative lack of pro-arrhythmia, although its non-cardiac toxicities limit its use. Some investigational agents are directed at multiple ion channels, or are designed to be analogs of amiodarone. The other line of investigation focuses on the antiarrhythmic action of agents that affect novel ion channel targets. Basic and early clinical studies show promise for drugs that provide atrial antiarrhythmic effects without ventricular pro-arrhythmia by affecting the atrium preferentially or selectively (inhibiting the I(TO) and I(Kur) currents, respectively). Future drugs may possess preferential effects on the remodeled atrium (and as such would be selective for patients with atrial fibrillation). It is hoped that efforts to develop new drugs, including those with preferential effects on the atrium, will provide therapy with greater efficacy and safety.
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
01:25Dysrhythmias VI: Management of Dysrhythmias
01:30Heart Failure V: Medical Management
01:25Mitral Regurgitation III: Medical Management
01:21Rheumatic Heart Disease III: Medical Management
01:25Aortic Regurgitation III: Medical Management